Kyprolis 60 Mg/50 Ml 60 mg/50 ml Powder for solution for infusion
PDF Leaflet Revision Date: 01 March 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of relapsed or refractory multiple myeloma.
Dosage (summary)
IV infusion, starting at 20 mg/mu00b2, increased to 27 mg/mu00b2 or 56 mg/mu00b2 based on regimen.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- Dexamethasone
- Lenalidomide
- Daratumumab
Contraindications
- Hypersensitivity to carfilzomib
- Breastfeeding
Common side effects
- Anaemia
- Thrombocytopenia
- Neutropenia
- Nausea
- Fatigue
Counselling Points
- Hydration required before treatment
- Monitor for infusion reactions
- Use effective contraception during treatment
Serious warnings
- Cardiac failure
- Pulmonary toxicity
- Acute renal failure
- Tumor lysis syndrome
Important Disclaimer
The Kyprolis 60 Mg/50 Ml 60 mg/50 ml Powder for solution for infusion professional information leaflet below is the property of Amgen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
